

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM450462

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
NATIONAL BANK OF CANADA		11/08/2017	Corporation:
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	HI-VIDOMIN LABORATORIES, INC.		
<b>Street Address:</b>	490 Boston Post Road		
<b>City:</b>	Sudbury		
<b>State/Country:</b>	MASSACHUSETTS		
<b>Postal Code:</b>	01776		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 4</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	2065143	G.F.S.-2000	
<b>Registration Number:</b>	2079110	DL-WINTER FORMULA	
<b>Registration Number:</b>	2210607	D.L. DUO-DOPHILUS	
<b>Registration Number:</b>	2242741	C-MAX	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2127352000		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	212.735.5117		
<b>Email:</b>	francine.waldbaum@skadden.com		
<b>Correspondent Name:</b>	Skadden, Arps, Slate, Meagher & Flom LLP		
<b>Address Line 1:</b>	Four Times Square		
<b>Address Line 2:</b>	Francine Waldbaum		
<b>Address Line 4:</b>	New York, NEW YORK 10036		
<b>ATTORNEY DOCKET NUMBER:</b>	099360/80		
<b>NAME OF SUBMITTER:</b>	Cristina Vasile		
<b>SIGNATURE:</b>	/Cristina Vasile/		
<b>DATE SIGNED:</b>	11/10/2017		
<b>Total Attachments: 3</b>			

CH \$115.00 2065143

source=Aisle\_NBC\_TM\_Release\_3693\_0565#page1.tif  
source=Aisle\_NBC\_TM\_Release\_3693\_0565#page2.tif  
source=Aisle\_NBC\_TM\_Release\_3693\_0565#page3.tif

## RELEASE OF SECURITY INTEREST IN TRADEMARKS

This RELEASE OF SECURITY INTEREST IN TRADEMARKS, dated as of November 8th, 2017 (this “Release”), is made by NATIONAL BANK OF CANADA, a Canadian corporation, having a place of business at 1155 Metcalfe Street, 5<sup>th</sup> Floor, Montreal, Quebec H3B 4S9 as Administrative Agent and/or Creditor (in such capacity, together with any successor thereto in such capacity, the “Assignor”), in favor of HI-VIDOMIN LABORATORIES, INC., a Delaware corporation, having a place of business at 490 Boston Post Road, Sudbury, Massachusetts 01776 (the “Assignee”). All capitalized terms used but not otherwise defined herein have the meanings given to them in the Security Agreement (as defined below).

### WITNESSETH

WHEREAS, Atrium Biotechnologies Inc., a corporation organized under the laws of Canada that was the direct or indirect corporate parent of Assignee, and Assignor, amongst others, entered into a credit agreement dated as of January 17, 2005 (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), pursuant to which the lenders thereunder agreed to grant credit to Atrium Biotechnologies Inc. from time to time, subject to the terms and conditions set forth therein;

WHEREAS, Assignee and Assignor, amongst others, entered into a U.S. security and pledge agreement dated as of January 17, 2005, as amended and restated (collectively, the “Security Agreement”), pursuant to which Assignee pledged, assigned and granted to Assignor for the benefit of the Creditors a first priority Lien upon and a continuing first priority security interest in all of Assignee’s rights, title and interests in, to and under, amongst other things, all trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos and other source or business identifiers, and the goodwill associated therewith, then existing or thereafter adopted or acquired by Assignee, all registrations and recordings thereof, and all applications in connection therewith, whether in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof, or otherwise, and all renewals thereof, whether then owned or thereafter acquired and wherever located, and whether then existing or thereafter arising or created, including, without limitation, the trademarks and trademark applications listed in Schedule A hereto (collectively, the “Trademark Collateral”);

WHEREAS, the Security Agreement was recorded with the United States Patent and Trademark Office on January 10, 2008 at Reel/Frame No. 3693/0565; and


WHEREAS, Assignor has agreed to release its Lien upon and continuing security interest in the Trademark Collateral and re-assign and transfer all of its right, title and interest in the Trademark Collateral to Assignee.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby releases its Lien upon and continuing security interest in all of the Trademark Collateral, and re-assigns and transfers any right, title and interest that Assignor may have in the Trademark Collateral to Assignee.

[SIGNATURE PAGE FOLLOWS]


IN WITNESS WHEREOF, Assignor has caused this Release to be duly executed and delivered by its duly authorized officer as of the date first written above.

**NATIONAL BANK OF CANADA**

Per:  \_\_\_\_\_

Name: Dominic Albanese \_\_\_\_\_

Title: Managing Director \_\_\_\_\_

Per:  \_\_\_\_\_

Name: Bruno Lévesque \_\_\_\_\_

Title: Managing Director \_\_\_\_\_

**SCHEDULE A**

**TO  
RELEASE OF SECURITY INTEREST  
IN TRADEMARKS**

**U.S. Trademark Registrations**

<b>Registered Owner</b>	<b>Jurisdiction</b>	<b>App. No.</b>	<b>Reg No.</b>	<b>Mark</b>
Hi-Vidomin Laboratories, Inc.	United States	75/127857	2065143	G.F.S.-2000
Hi-Vidomin Laboratories, Inc.	United States	75/128360	2079110	DL-WINTER FORMULA
Hi-Vidomin Laboratories, Inc.	United States	75/348108	2210607	D.L. DUO-DOPHILUS
Hi-Vidomin Laboratories, Inc.	United States	75/440590	2242741	C-MAX